<DOC>
	<DOCNO>NCT02778854</DOCNO>
	<brief_summary>The purpose study evaluate diagnostic prognostic efficacy liquid biopsy different specimen different method compare tissue detection .</brief_summary>
	<brief_title>Liquid Biopsy Detection Driver Mutation NSCLC</brief_title>
	<detailed_description>Collect plasma specimens patient newly diagnose NSCLC drug-resistant plan receive gene detection complete diagnostic test liquid biopsy .Participants come diagnostic test plan receive tyrosine kinase inhibitor ( TKI ) therapy collect plasma specimen every month regiment monitor change driver motion predict prognosis target therapy .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>cohort 1 patient newly diagnose NSCLC confirm tissue biopsy go receive detection gene mutation patient obtain drugresistance receive molecular target therapy plan rebiopsy . Age â‰¥ 18 year newly diagnose patient receive TKI chemotherapy patient drugresistant receive nextgeneration TKI patient one type carcinoma patient reject sign inform consent cohort 2 patient cohort1 sensitive driver mutation plan receive TKI therapy patient regular followup Chinese people liberation army general hospital every month . patient refuse provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>liquid biopsy</keyword>
	<keyword>driver mutation</keyword>
</DOC>